▲ +15.09% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for InMode in the last 3 months. The average price target is $47.75, with a high forecast of $55.00 and a low forecast of $38.00. The average price target represents a 15.09% upside from the last price of $41.49.
The current consensus among 4 polled investment analysts is to buy stock in InMode.
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. The company offers minimally-invasive aesthetic medical products for procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. InMode Ltd. offers its products directly in the United States, Canada, the United Kingdom, Spain, and India, as well as indirectly through third-party distributors internationally. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.